Cannabis News

Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Launches Health & Wellness Podcast; Secures Features in Top Brazil Lifestyle Publications


SAN DIEGO, Calif., July 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWireMedical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chains, announced today today that its subsidiary HempMeds® Brazil created a new podcast focused on health and wellness PodioCast and, as a result, has been featured in several leading news publications in Brazil, such as Globo’s Galileu magazine (pictured below), sports lifeand the Podcast Desobediência Productiva.

PodioCast is hosted by actress and presenter Rachel Apollonio, Executive Director of HempMeds® Brasil, Matheus Patelli, and veteran journalist and HempMeds® marketer, Marcus Bruno. Each episode features interviews with athletes and medical professionals to talk about the challenges and wellness routines of top athletes and active consumers.

“Our podcast’s mission is to help break the stigma around CBD and cannabis and educate people on how they can incorporate it into their lives,” said Matheus Patelli, Executive Director of HempMeds® Brasil. . “We have already been able to secure exclusive interviews with a variety of influential X-Games winners, MMA and boxing world champions and other Olympic medalists and these articles have been a great help to us in promoting the podcast. .”

In addition to the podcast, these articles explain how the World Anti-Doping Agency (WADA) removed CBD from its list of prohibited substances in 2018 and since then more and more athletes, professional and amateur, in Brazil have started to use CBD products. , such as those offered by HempMeds®.

They also highlight how HempMeds® has been dedicated to educating patients and physicians about cannabidiol (CBD) since the company’s inception. HempMeds® education initiatives include online academic resources, in-person and virtual medical education courses to educate physicians on cannabinoid treatments and discuss the principles of the human endocannabinoid system, as well as sponsorships of global seminars on the CBD and specific conditions aimed at helping patients with legal issues. guidelines, finding doctors and financial support.

“We are happy to have pioneered the introduction of non-psychoactive cannabis in Brazil. Our hope is that enthusiasts all over Brazil tune in to the podcast to learn more and play a part in our movement,” said Medical Marijuana, Inc. CEO Blake Schroeder. “We hope our customers will see HempMeds’ new podcast as a testament to our mission to provide free, informed access to CBD around the world.”

To learn more about HempMeds® Brasil, please visit www.hempmeds.com.br.

About HempMeds® Brazil

HempMeds® Brasil was the first company to receive approval from the National Health Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is licensed to supply its products, which help control diseases such as epilepsy, Parkinson’s disease, chronic pain and multiple sclerosis, under medical prescription. For these indications, products may be subsidized by the Brazilian government. HempMeds® Brasil is working on additional approvals for other indications. www.hempmeds.com.br.

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc.. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Genuine Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and effectiveness.

Medical Marijuana, Inc. is headquartered in San Diego, CA and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To view the Medical Marijuana, Inc. corporate video, Click here.

PROSPECTIVE DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

LEGAL DISCLOSURE

Medical Marijuana, Inc. does not sell or distribute products that violate the US Controlled Substances Act.

CONTACT:
Public relations contact:
Katherine Brown
Account director
CMW Media
858-221-8001
[email protected]
www.cmwmedia.com

Contact with Investor Relations:
T. (858) 283-4016
[email protected]



#Medical #Marijuana #Subsidiary #HempMeds #Brasil #Launches #Health #Wellness #Podcast #Secures #Features #Top #Brazil #Lifestyle #Publications

Related Posts

Leave a Reply